Table 2 Number of studies found for each pair of drugs/biomarkers and their outcomes
Pair drug/biomarker | Number of Studies | Outcomes | |
|---|---|---|---|
Clomipramine | CYP1A2 | 0 | Not applicable |
CYP3A4 | 1 | Lack of effectiveness | |
Undesirable effects | |||
CYP2C19 | 6 | Lack of effectiveness | |
Undesirable effects | |||
CYP2D6 | 7 | Undesirable effects | |
CYP2C9 | 1 | Information not available | |
Maprotiline | CYP1A2 | 0 | Not applicable |
CYP2D6 | 0 | Not applicable | |
Fluoxetine | CYP2D6 | 5 | Lack of effectiveness |
Undesirable effects | |||
Interactions | |||
CYP2C9 | 2 | Information not available | |
CYP2C19 | 3 | Undesirable effects | |
Citalopram | CYP3A4 | 0 | Not applicable |
CYP2C19 | 12 | Lack of effectiveness | |
Undesirable effects | |||
CYP2D6 | 4 | Undesirable effects | |
CYP3A4 | 1 | Information not available | |
Sertraline | CYP3A4 | 0 | Not applicable |
CYP2C19 | 6 | Lack of effectiveness | |
Undesirable effects | |||
CYP2D6 | 1 | Information not available | |
CYP2B6 | 2 | Lack of effectiveness | |
Undesirable effects | |||
Fluvoxamine | CYP2D6 | 3 | Lack of effectiveness |
Undesirable effects | |||
CYP2C19 | 1 | Information not available | |
Escitalopram | CYP3A4 | 0 | Not applicable |
CYP2C19 | 6 | Lack of effectiveness | |
Undesirable effects | |||
CYP2D6 | 4 | Information not available | |
Moclobemide | CYP2C19 | 0 | Not applicable |
CYP2D6 | 0 | Not applicable | |
Trazodone | CYP3A4 | 1 | Information not available |
CYP2D6 | 2 | Undesirable effects | |
Mirtazapine | CYP1A2 | 2 | Information not available |
CYP3A4 | 0 | Not applicable | |
CYP2D6 | 4 | Lack of effectiveness | |
Undesirable effects | |||
CYP2B6 | 1 | Information not available | |
Bupropion | CYP1A2 | 0 | Not applicable |
CYP2A6 | 0 | Not applicable | |
CYP3A4 | 0 | Not applicable | |
CYP2B6 | 7 | Lack of effectiveness | |
Undesirable effects | |||
Interactions | |||
CYP2C9 | 1 | Information not available | |
CYP2E1 | 0 | Not applicable | |
CYP2D6 | 1 | Information not available | |
CYP2C19 | 2 | Lack of effectiveness | |
Venlafaxine | CYP3A4 | 3 | Information not available |
CYP2D6 | 17 | Lack of effectiveness | |
Undesirable effects | |||
CYP2C19 | 9 | Interactions | |
Reboxetine | CYP3A4 | 0 | Not applicable |
Duloxetine | CYP1A2 | 1 | Lack of effectiveness |
CYP2D6 | 1 | Information not available | |
Agomelatine | CYP1A2 | 2 | Undesirable effects |
CYP2C9 | 1 | Information not available | |
CYP2C19 | 0 | Not applicable | |
Vortioxetine | CYP3A4 | 0 | Not applicable |
CYP3A5 | 0 | Not applicable | |
CYP2C9 | 0 | Not applicable | |
CYP2D6 | 0 | Not applicable | |